Skip to content

Different Doses of Oliceridine Combined with Flurbiprofen Axetil for Postoperative Analgesia After Gynecological Laparoscopic Surgery: A Randomized Clinical Controlled Trial

Different Doses of Oliceridine Combined with Flurbiprofen Axetil for Postoperative Analgesia After Gynecological Laparoscopic Surgery: A Randomized Clinical Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500112855
Enrollment
Unknown
Registered
2025-11-20
Start date
2025-12-01
Completion date
Unknown
Last updated
2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients Undergoing Gynecologic

Interventions

Low dose Oliceridine group (A group):The postoperative intravenous patient-controlled analgesia (PCA) pump was prepared with oliceridine 0.3 mg/kg plus flurbiprofen axetil 150 mg and azasetron 10 mg,
Medium dose Oliceridine group (B group):The postoperative intravenous patient-controlled analgesia (PCA) pump was prepared with oliceridine 0.4 mg/kg plus flurbiprofen axetil 150 mg and azasetron 10 m
High dose Oliceridine group (C group):The postoperative intravenous patient-controlled analgesia (PCA) pump was prepared with oliceridine 0.5 mg/kg plus flurbiprofen axetil 150 mg and azasetron 10 mg,

Sponsors

Tongling People’s Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1)Aged 18-65 years; (2)ASA classification I–III; (3)18 kg/m^2 <= BMI <= 28kg/m^2 (4)Scheduled elective gynecological laparoscopic surgery; (5)Expected duration of surgery between 1 and 3 hours; (6)Written informed consent for anesthesia signed by all patients prior to surgery.

Exclusion criteria

Exclusion criteria: (1)Dysfunction of vital organs such as the heart, liver, or lungs; (2)Allergy or contraindication to any anesthetics, adjunct analgesics, rescue analgesics, antiemetics, or antibiotics used in the study; (3)Patients with chronic pain and/or those on long-term sedative or analgesic medication; (4)Central nervous system or psychiatric disorders, or inability to communicate; (5)QTc interval > 470 ms; (6)Coagulopathy; (7)Active peptic ulcer or a history of gastrointestinal bleeding; (8)Pregnant or breastfeeding women.

Design outcomes

Primary

MeasureTime frame
Resting and movement VAS pain scores;

Secondary

MeasureTime frame
Resting and movement VAS pain scores;Incidence of Postoperative Adverse Events (Nausea ,Somnolenc,Respiratory depression, Pruritus);The total and effective number of patient?controlled analgesia (PCA) button presses within 48?hours after surgery, as well as the rate of rescue analgesia, were recorded. Total and effective PCA presses within 48?hours postoperatively and the rescue analgesia rate were documented. ?? Patient?controlled analgesia (PCA):. ? total PCA presses total number of PCA button presses. ? effective PCA presses successful PCA attempts. ? rescue analgesia;Ramsay scores;Quality of Recovery-15 (QoR-15) score;The time to first postoperative flatus and the postoperative length of hospital stay were recorded for all patients.;

Countries

China

Contacts

Public ContactJiang Xuehui

Tongling People’s Hospital

19056952035@163.com+86 190 5695 2035

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026